Candel Therapeutics, Inc. Balance Sheet
CADL|3 years of annual SEC 10-K data (FY2021-FY2023)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Candel Therapeutics, Inc. had $41M in total assets and $13M in shareholders' equity as of FY2023. Total debt was $12M against $35M in cash, resulting in a $24M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Cash & Equivalents | $35.4M | $70.1M | $82.6M |
| Current Assets | $36.8M | $71.9M | $84.9M |
| PP&E (Net) | $3.2M | $4.4M | $3.8M |
| Total Assets | $41.2M | $77.7M | $89.2M |
| Current Liabilities | $14.2M | $5.6M | $5.4M |
| Total Debt | $11.6M | - | - |
| Shareholders' Equity | $12.7M | $64.1M | -$23.6M |